Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?

Georgios Christodoulidis; Usman Baber; Roxana Mehran

doi:10.1097/HCO.0000000000000070

Back

Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?

Journal article

Peer reviewed

Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?

Georgios Christodoulidis, Usman Baber and Roxana Mehran

Current opinion in cardiology, Vol.29(4), pp.301-306

07/2014

DOI: 10.1097/HCO.0000000000000070

PMID: 24842783

View Online

Abstract

To provide updates regarding the optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS). Within the past years, five moderate-sized randomized controlled trials evaluated different DAPT durations after percutaneous coronary intervention. These studies included a significant percentage of ACS patients that varied from 30 to 75% depending on the study. Results suggest that in selected populations prolonging DAPT does not offer additional protection from ischemic events and increases bleeding complications. However, results from a large-scale registry illustrate that DAPT durations beyond 6 months are associated with lower cardiovascular risk. Moreover, a multicenter registry demonstrated that the context underlying DAPT cessation is an additional correlate of outcomes after stent implantation. Current guidelines suggest 12 months of DAPT after an initial presentation with ACS. Emerging evidence suggest that in selected populations shorter duration might be acceptable.

Purinergic P2Y Receptor Antagonists - administration & dosage

Ticlopidine - therapeutic use

Humans

Myocardial Ischemia - prevention & control

Ticlopidine - analogs & derivatives

Aspirin - administration & dosage

Randomized Controlled Trials as Topic

Acute Coronary Syndrome - drug therapy

Time Factors

Platelet Aggregation Inhibitors - administration & dosage

Ticlopidine - administration & dosage

Aspirin - therapeutic use

Platelet Aggregation Inhibitors - therapeutic use

Stents

Percutaneous Coronary Intervention

Purinergic P2Y Receptor Antagonists - therapeutic use

Details

Title: Subtitle: Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Creators: Georgios Christodoulidis - aThe Icahn School of Medicine at Mount Sinai bCardiovascular Research Foundation, New York, NY, USA
Usman Baber
Roxana Mehran
Resource Type: Journal article
Publication Details: Current opinion in cardiology, Vol.29(4), pp.301-306
DOI: 10.1097/HCO.0000000000000070
PMID: 24842783
ISSN: 0268-4705
eISSN: 1531-7080
Language: English
Date published: 07/2014
Academic Unit: Cardiovascular Medicine; Internal Medicine
Record Identifier: 9984094332102771

Metrics

25 Record Views

1 Times Cited - Web of Science

See more details